Skip to main
RNXT

RenovoRx (RNXT) Stock Forecast & Price Target

RenovoRx (RNXT) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

RenovoRx is a clinical-stage biopharmaceutical company with a positive outlook due to its current valuation attractiveness, strong potential for market growth in its lead drug therapy candidate RenovoGem, and successful commercialization of its FDA-cleared RenovoCath medical device. The company has a solid balance sheet, no debt, and has recently reported positive interim analysis results from its Phase 3 TIGeR-PaC trial. With a focus on precision oncology therapies and a new CFO with a strong background, RenovoRx is well-positioned for success in the future, with risks including product safety and efficacy demonstration, regulatory approvals, and competition.

Bears say

RenovoRx is currently in a strong position with positive revenue growth and a new CFO with a solid background in the technology sector. Their lead drug therapy candidate, RenovoGem, is in a Phase 3 registration trial, but the company will need to achieve success in this trial in order to see significant revenue growth in the future. Additionally, while the market potential is large, there are also risks associated with drug development that could impact the company's success and potential stock performance in the future.

RenovoRx (RNXT) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of RenovoRx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About RenovoRx (RNXT) Forecast

Analysts have given RenovoRx (RNXT) a Strong Buy based on their latest research and market trends.

According to 2 analysts, RenovoRx (RNXT) has a Strong Buy consensus rating as of Sep 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

RenovoRx (RNXT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.